1. Home
  2. LOAN vs XLO Comparison

LOAN vs XLO Comparison

Compare LOAN & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$3.94

Market Cap

47.6M

Sector

Real Estate

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.09

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LOAN
XLO
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.6M
56.9M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
LOAN
XLO
Price
$3.94
$9.09
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
22.7K
8.3K
Earning Date
04-16-2026
05-14-2026
Dividend Yield
10.06%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$8,666,307.00
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
$18.57
N/A
Revenue Growth
N/A
589.88
52 Week Low
$3.89
$0.46
52 Week High
$5.79
$9.90

Technical Indicators

Market Signals
Indicator
LOAN
XLO
Relative Strength Index (RSI) 34.17 49.23
Support Level $3.90 $8.52
Resistance Level $4.15 $9.15
Average True Range (ATR) 0.06 0.29
MACD -0.01 0.00
Stochastic Oscillator 5.86 46.74

Price Performance

Historical Comparison
LOAN
XLO

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: